OncoMatch/Clinical Trials/NCT06863233
A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer
Is NCT06863233 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Zirconium Zr 89 crefmirlimab berdoxam for lung cancer.
Treatment: Zirconium Zr 89 crefmirlimab berdoxam — The purpose of this study to learn whether PET/CT (positron emission tomography/computed tomography) scans using an imaging agent (radiotracer) called zirconium Zr 89 crefmirlimab berdoxam is a safe and effective way to identify CD8+ T cells
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Disease stage
Metastatic disease required
Prior therapy
Must have received: engineered TIL cell therapy — enrolled but not yet treated
Patient is enrolled in the engineered TIL cell therapy protocol OBX115-23-01, but has not received the treatment yet.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering at Basking Ridge (Consent Only) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Consent Only) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Consent Only) · Montvale, New Jersey
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent only) · Commack, New York
- Memorial Sloan Kettering Westchester (Consent only) · Harrison, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify